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HIGHLIGHTS 
•	 Portable colposcopy is an effective and easy tool for cervical cancer screening in remote, low-resource settings.
•	 Human papillomavirus testing with portable colposcopy has higher sensitivity for detection than either method alone.
•	 Portable colposcopy should be considered part of the screening program in low-resource settings in China.
AbSTrACT
Objective To evaluate the use of a portable, rechargeable 
colposcope combined with human papillomavirus (HPV) 
testing, as compared with HPV testing alone, for screening 
of cervical cancer and pre-cancerous lesions.
Methods This was a cross-sectional study among 488 
women in Baoshan County, Yunnan. The women underwent 
HPV testing followed by Gynocular portable colposcopy 
with visual inspection with acetic acid. Obvious lesions 
were biopsied. If portable colposcopy testing was negative 
but HPV testing was positive, the women underwent 
follow-up testing with thin-prep cytology and traditional 
colposcopy. Cervical biopsies were performed for any 
abnormalities. Histopathology was followed up with 
diagnosis and treatment.
results Among 488 women screened with portable 
colposcopy, 24 women underwent biopsy based on 
positive colposcopy screening. Of these 24 women, three 
were HPV positive and 21 were HPV negative. Five women 
had cervical intra-epithelial neoplasia (CIN) I and one 
had advanced cervical cancer. Forty-six women tested 
positive for HPV. Three of these women had screened 
positive on preliminary colposcopy, with one positive for 
CIN III/squamous cell carcinoma and one woman with CIN 
I. Forty-three women underwent follow-up testing with 
thin-prep cytology. Two women had atypical squamous 
cells of undetermined significance and five had low-grade 
squamous intra-epithelial lesions and were biopsied; 
three women had CIN I, one had CIN II and one had CIN III. 
HPV testing and portable colposcopy was more sensitive 
but slightly less specific than portable colposcopy or HPV 
testing alone.
Conclusion While HPV testing has high sensitivity 
and specificity for the detection of pre-cancerous and 
cancerous lesions and portable colposcopy has lower 
specificity, both methods of detection have low positive 
predictive value and high negative predictive value. In 
tandem, HPV testing and portable colposcopy had higher 
sensitivity for detection among women who underwent 
biopsies. In clinical practice, portable colposcopy was an 
effective, easy and affordable tool to transport to villages 
where cytology is not currently feasible.
InTrOduCTIOn
Over the past 50 years, cervical cancer morbidity 
and mortality has been greatly reduced due to 
earlier detection and treatment of pre-cancerous and 
cancerous lesions. However, cervical cancer remains 
among the most common gynecologic cancers in 
China. According to the 2015 China Cancer Statis-
tics Data, the incidence of cervical cancer in 2015 
was 98.9/10 000, with 11.3/10 000 originating from 
China’s Southwest provinces, including Yunnan.1 
Among women age 30–44 years, the incidence of 
cervical cancer was second only to breast cancer.1 
Many women in more remote rural regions still lack 
any form of cervical cancer screening throughout 
their lifetime due to the economic and geographic 
challenges hindering access to care. Thus, cervical 
cancer screening in underserved regions of China 
remains a critical public health problem.
In the USA, the success of widespread screening 
over the past 60 years has reduced morbidity and 
mortality due to cervical cancer by 70%.2 In 2006, 
the American Society for Colposcopy and Cervical 
Pathology published guidelines recommending a 
combined screening protocol with cytology and 
human papillomavirus (HPV) testing. The current US 
screening guidelines recommend cytology every 3 
years for women age 21–29 years, and for women 
aged 30–65 screening every 3 years with cytology 
alone, every 5 years with high-risk HPV testing alone, 
or every 5 years with high-risk HPV testing in combi-
nation with cytology.3
In low and middle income countries, however, 
there is a dearth of effective, replicable screening 
programs; thus, many programs focus on finding 
alternative cost-effective approaches. Several large-
scale studies have demonstrated that HPV detection 
is superior to cytology for detection of high-grade 
cervical lesions.4–7 In one large-scale randomized 
controlled trial in Italy, HPV-based screening was 
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found to be more effective than cytology in the prevention of inva-
sive cervical cancer. This was attributed to better efficacy in early 
detection of clinically relevant lesions, treatment of cancers before 
invasion, and the ability to detect pre-cancerous changes that may 
not be clinically visible or even detectable with cytology.4 Further-
more, five trials with combined HPV and cytology testing versus 
HPV screening alone found that the overall combination was not 
more sensitive than sole HPV screening.5–9
While HPV has higher sensitivity than cytology and visual inspec-
tion with acetic acid, both visual inspection with acetic acid and 
cytology are more specific than HPV testing. However, it is also 
notable that the efficacy of cytologic examination and visual inspec-
tion with acetic acid may be influenced by the physician’s skillset 
and may affect replicability of studying these methodologies.
For rural areas with limited medical resources, it is important 
to implement an appropriate cervical cancer screening program 
that takes into consideration local resource constraints in order 
to be feasible and sustainable. Portable colposcopy is a simplified 
version of traditional colposcopy, and it has the potential to improve 
the efficacy of visual screening methods.10 It is low-cost and easy 
to handle, which could help improve the feasibility. However, the 
validity of portable colposcopy requires further examination.
In this study we used a combination of HPV testing with portable 
colposcopy to compare the sensitivity and specificity of this 
combined screening method versus HPV testing alone. In February 
2017, 488 women were screened in four townships of Yunnan 
Province.
METHOdS
This study was conducted across four towns of Longyang District, 
Baoshan City, Yunnan Province, including Wafang, Yangliu, Yangyi 
and Xiyi, between February 12 and February 26, 2017. The protocol 
was approved by the Ethics Committees of The First People’s 
Hospital of Yunnan and The Maternal and Child Health and Family 
Planning Service Center of Longyang District. Screening was incor-
porated with pre-existing screening, with HPV and subsequent thin-
prep cytology being offered by the Chinese government through a 
rural women’s health screening program. This government-spon-
sored program is part of a larger rural women’s health screening 
program which offers no-cost screening to women in remote 
villages.
Women were informed before the arrival of the medical team 
that cervical cancer screening would be taking place at the local 
clinics on a specified date and the government screening protocol 
mandated attendance for all women in the village. Two qualified 
gynecologists (HJ, BF) from The First People’s Hospital of Yunnan 
and The Maternal and Child Health and Family Planning Service 
Center of Longyang District performed all screening examinations.
Women were excluded from the study if they had a known history 
of cervical intra-epithelial neoplasia or cervical cancer, hysterec-
tomy with cervix removal, pre-existing conditions inhibiting safe 
examination (clotting or bleeding disorders), or the inability to 
provide informed consent.
All participants of this study underwent HPV testing and Gynoc-
ular (Gynius AB, Sweden) examination. The data were exam-
ined retrospectively to compare sensitivity, specificity, negative 
predictive value and positive predictive value of HPV and Gynocular 
testing versus HPV testing alone for the diagnosis of cervical cancer 
or pre-cancerous lesions.
Two qualified gynecologists performed the colposcopy examina-
tions (HJ, BF) with the Gynocular colposcope. Photographs were 
taken with an iPhone 6 and an iPhone 6S. The examination opera-
tion was guided by China’s Ministry of Health manual Technical Plan 
for Cervical Cancer Examination Project for Rural Women's Health.
Each woman was examined in a private clinic room. Subjects 
were asked to lie in a supine position for initial external inspec-
tion of the vulva and vagina. Using a portable speculum covered in 
plastic that was disposed of after each usage, the vagina and cervix 
were examined and HPV testing was then performed.
Cervical samples were obtained from women using a cytobrush 
for genomic DNA extraction. After HPV sampling was performed, 
the Gynocular portable colposcope was used to examine the cervix 
in the methodology typically performed with traditional colpos-
copy examination. First 3% acetic acid was applied for 30 s and 
observation was made lasting at least 2 min. Inspection was then 
performed after application of Lugol’s 5% iodine.
If there was an obvious lesion by Gynocular examination, a 
biopsy was performed for histopathologic testing at the time of the 
examination unless the woman was currently menstruating or there 
was microscopic abnormal vaginal discharge suggesting infection. 
If the sample could not be obtained at the time of the examina-
tion, the participants were contacted for follow-up screening and 
treatment at The Maternal and Child Health and Family Planning 
Service Center of Longyang District 3 to 7 days after the cessation 
of menses or improvement of vaginal infection.
If the portable colposcopy testing was negative but HPV testing 
was subsequently found to be positive, women then had follow-up 
testing with thin-prep cytology and traditional colposcopy. Cervical 
biopsies were performed if there were any abnormalities. All histo-
pathologic abnormalities were followed up with specific diagnosis 
and treatment, including loop electrosurgical excision procedure, 
cold knife conization or clinical follow up.
HPV detection and histopathology
HPV testing was performed by the PCR Laboratory of The National 
Health Commission’s Key Laboratory, The First People's Hospital 
of Yunnan Province by liquid suspension chip technology with the 
Luminex 200 (Luminex Corp). Samples were stored at 4° C after 
collection and sent to The First People’s Hospital of Yunnan for HPV 
genotyping. The Luminex-based HPV genotyping has been shown 
to be a highly sensitive, reproducible technique for simultaneous 
genotyping of genital HPV types.11 Target high-risk oncogenic types 
included: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. 
Thin-prep cytology and biopsies were interpreted by the Depart-
ment of Pathology of the First People’s Hospital of Yunnan Province.
The data were recorded and processed by Microsoft Excel, SPSS 
13.0.
rESuLTS
A total of 488 women aged 30 to 60 years (mean age 44.3±6.6 
years) were screened with combined HPV testing and portable 
colposcopy. The demographic details of the study participants 
are provided in Table  1. Among these women, 59.3% had never 
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Table 1 Characteristics of participants in the study
Variables (n=488) n %
Age (years)
  30–34 43 8.8
  35–39 76 15.6
  40–44 126 25.8
  45–49 122 25.0
  50–54 101 20.7
  55–60 20 4.1
Education
  None 16 3.3
  Primary 292 59.8
  Middle school 158 32.4
  High school 16 3.3
  Graduate 6 1.2
Menopause
  Post-menopausal 77 15.8
  Pre-menopausal 403 82.6
  Peri-menopausal 8 1.6
Childbearing
  Nil 3 0.6
  1–3 485 99.4
Lifetime number of 
sexual partners
  One 486 99.6
  Two 2 0.4
Figure 1 Flow diagram of participation and methodology of evaluation by human papillomavirus screening, portable 
colposcopy, thin-prep cytology and histologic biopsies. ASCUS, atypical squamous cells of undetermined significance; CIN, 
cervical intra-epithelial neoplasia; HPV, human papillomavirus; LSIL, low-grade squamous intra-epithelial lesions; NILM, 
negative for intra-epithelial lesion or malignancy; TCT, thin-prep cytology; VIA, visual inspection with acetic acid.
Table 2 Human papillomavirus (HPV) genotypes detected 
among study participants
HPV genotype n %
16 4 0.8
18 4 0.8
31 1 0.2
33 5 1.0
35 2 0.4
39 3 0.6
45 0 0
51 1 0.2
52 15 3.1
56 7 1.4
58 6 1.2
59 6 1.2
66 1 0.2
68 4 0.8
received any prior cervical cancer screening, and only 16.2% 
reported having been screened within the past 3 years. A flow 
diagram is shown in Figure 1.
Of the 488 women screened, 46 (9.4%) tested positive for HPV. 
A single HPV type was detected in 34 women, while 12 women 
were co-infected with multiple genotypes (nine women with two 
genotypes, three women with three genotypes). The most common 
subtypes were HPV 52 and HPV 56. Results are shown in Table 2.
Among the 488 women screened with portable colposcopy, 24 
women (4.9%) underwent biopsy based on visual inspection with 
acetic acid-positive colposcopy screening. Of these women, 20 
biopsies were obtained at the time of the initial colposcopy exam-
ination, while four were obtained later due to concern for infection 
or menstruation at the time of the initial examination. Of these 24 
women, three were HPV positive and 21 were HPV negative.
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Table 3 Histopathology results from women screening 
positive with portable colposcopy
Negative (including cervicitis) 18
CIN I 5
CIN II 0
CIN III 0
Invasive cervical cancer 1
CIN, cervical intra-epithelial neoplasia.
Table 4 Histopathology results from women screening 
positive with human papillomavirus testing and subsequent 
thin-prep cytology
Histopathology Number
Cervicitis 2
CINI 3
CIN II 1
CIN III 1
Cancer 0
CIN, cervical intra-epithelial neoplasia.
Table 5 Sensitivity, specificity, positive predictive value 
and negative predictive value of human papillomavirus 
screening, portable colposcopy, and combined screening 
method for detection of pre-cancerous and cancerous 
cervical lesions
Screening modality
Sensitivity 
(%)
Specificity 
(%)
PPV 
(%)
NPV 
(%)
HPV testing alone 63.6 91.8 15.2 99.1
Portable colposcopy 
testing alone
54.6 96.2 25.0 98.9
HPV testing and 
portable colposcopy 
combined
100 88.3 16.4 100
HPV, human papillomavirus; NPV, negative predictive value; PPV, 
positive predictive value.
Twenty-four women underwent cervical biopsies bases on posi-
tive screening by portable colposcopy examination. These results 
are reported in Table 3.
Forty-six women tested positive for HPV. One of these women 
had screened positive on preliminary colposcopy and her biopsy 
resulted in cervical intra-epithelial neoplasia (CIN) III and squa-
mous cell carcinoma; she received treatment at The Maternal and 
Child Health and Family Planning Center. Another two women also 
had biopsies taken at the time of portable colposcopy and were 
diagnosed with CIN I and cervicitis. Finally, 43 women underwent 
follow-up testing with thin-prep cytology. Of these women, 36 were 
negative for intra-epithelial lesion or malignancy, two women had 
atypical squamous cells of unknown significance, and five had a 
low-grade squamous intraepithelial lesion.
All seven women with atypical squamous cells of unknown 
significance or low-grade squamous intra-epithelial lesion under-
went biopsies. Their pathology results are shown in Table 4.
Women were categorized as disease positive if they were biop-
sied and the result demonstrated pre-cancerous or cancerous 
lesions, from CIN I through to squamous cell carcinoma. Women 
who were not biopsied because they had screened negative by 
portable colposcopy and were HPV negative or were HPV positive 
but subsequently had a negative thin-prep cytology result were 
considered true negatives for cancerous or pre-cancerous lesions.
The sensitivity, specificity, positive predictive value and negative 
predictive value of HPV screening alone, portable colposcopy alone, 
and combined screening with HPV and portable colposcopy for the 
detection of cancerous and pre-cancerous lesions (defined as CIN I 
through squamous cell carcinoma) are described in Table 5.
dISCuSSIOn
At present, cervical cancer screening in rural areas of Yunnan is 
supported by the local government by district with funding through 
the county level maternal and child health budget. There are many 
government-sponsored screening projects but no standardized 
screening methodology.
Thin-prep cytology sampling is feasible and quick to perform; 
however, many of the closest urban institutions do not have the 
technology or resources to carry out cytology or histopathology. 
Thus, they send these samples to other urban institutions at addi-
tional cost and follow up is challenging. Traditional colposcopy as 
performed in urban hospitals is not costly long-term, but the tradi-
tional scope is not easily transported outside of the clinic and it is 
not effective as a sole primary screening tool.
While HPVtesting has high sensitivity and specificity for the 
detection of pre-cancerous and cancerous lesions, and portable 
colposcopy has lower specificity, both methods of detection have 
low positive predictive value and high negative predictive value. In 
tandem, however, HPV testing with portable colposcopy had a much 
higher sensitivity for detection of pre-cancerous and cancerous 
lesions.
In clinical practice we also found that portable colposcopy was 
an easy and affordable tool to transport to the villages. The scopes 
are lightweight and have rechargeable batteries; therefore they do 
not require additional transport vehicles and manual support as was 
needed to carry a traditional colposcope. For these reasons, HPV 
testing combined with portable colposcopy may improve screening 
at a much lower cost, as the cost of colposcopy is significantly lower 
than thin-prep cytology. Furthermore, when an abnormal lesion is 
detected by portable colposcopy a biopsy can be performed imme-
diately, which helps obviate the challenges of follow up.
The results of this study were based on examinations performed 
by a trained and well-experienced gynecologist; thus, our results 
are not transferable to communities without access to a trained 
colposcopist. Additionally, the gold standard for calculating sensi-
tivity and specificity for cervical cancer screening is to have 
histopathology samples of cervical biopsies of all women who 
were screened (positive or negative).12 However, there were not 
sufficient resources to biopsy all women screened, and addition-
ally there are risks associated with cervical biopsy. Thus, in this 
study not all women were biopsied. Women who were negative by 
portable colposcopy examination and HPV testing were considered 
disease-free; thus, it is possible that there is some overestimation 
of sensitivity and specificity.
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Throughout China HPV16 and HPV18 are widespread strains 
among women with cervical cancer; however, there is variability of 
genotypes by region.13 In one study on the prevalence of HPV infec-
tion among nearly 30 000 Chinese women in Yunnan, the overall 
HPV prevalence was 12.9% with the three most prevalent high-risk 
HPV types being HPV52, HPV16 and HPV58. Age subgroup analysis 
also demonstrated bimodal peak prevalence: one among women 
under 25, and another among women over 56 years.14
In this study the overall prevalence of HPV (9.4%) was low when 
compared with rates throughout China and with a larger study in 
Yunnan (12.9%).12 Additionally, it is notable that the most common 
types of HPV (HPV52, HPV 56, HPV58 and HPV59) did not mirror 
overall prevalence throughout the country as described in larger 
studies and meta-analyses.
Major risk factors for HPV infection include number of sexual 
partners, age at first intercourse, smoking, low socioeconomic 
status, and taking oral contraceptive pills. The low prevalence of 
HPV among the population of women screened in this study may 
be multifactorial. First, the age range we studied was 30–60 years, 
with three-quarters of women over the age of 40. Thus, our study 
may have noted a higher prevalence had we also screened women 
under 25, given reports of bimodal distribution. Additionally, the 
majority of women in this study (99.6%) all reported only ever 
having had one sexual partner, and use of oral contraception pills 
and smoking is generally low in this region, decreasing their risk 
factors for acquiring HPV. Low number of sexual partners is not 
unique to this study; in another cross-sectional study looking at HPV 
seropositivity in rural China, 99.9% of women reported 0–2 lifetime 
partners and only 0.1% reported >3 lifetime partners.15 However, 
our study was a small sample size and may not be representative of 
overall prevalence among the rural population of women in Yunnan.
Future studies should examine the sensitivity and specificity 
of portable colposcopy as compared with traditional colposcopy. 
More research is warranted to determine with greater statistical 
significance whether HPV combined with portable colposcopy 
could be scaled up to improve the bandwidth of screening in 
remote areas at a much lower cost. Recent studies in Africa 
have also looked at the use of a screen-and-treat approach with 
immediate thermocoagulation treatment after positive screening 
for HPV with visual inspection with acetic acid.12 Connecting 
naked eye visual inspection with acetic acid or portable colpos-
copy with cell phones may also provide remote consultation for 
guiding same day therapy.16 17 Further research could examine 
the use of HPV testing in tandem with portable colposcopy and 
digital photography guiding same day treatment in rural China.
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